Akers Biosciences, Inc. Sample Contracts

FORM OF COMMON STOCK PURCHASE WARRANT AKERS BIOSCIENCES, INC.
Akers Biosciences, Inc. • November 18th, 2020 • In vitro & in vivo diagnostic substances

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ____________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jersey corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AutoNDA by SimpleDocs
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • April 5th, 2017 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances

This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 30, 2017, between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

UNDERWRITING AGREEMENT between AKERS BIOSCIENCES, INC. and JOSEPH GUNNAR & CO., LLC as Representative of the Several Underwriters AKERS BIOSCIENCES, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • December 15th, 2017 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

The undersigned, Akers Biosciences, Inc., a corporation formed under the laws of the State of New Jersey (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Akers Biosciences, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Joseph Gunnar & Co., LLC. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Akers Biosciences, Inc.
MyMD Pharmaceuticals, Inc. • March 31st, 2022 • In vitro & in vivo diagnostic substances • New York

THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 5, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jersey corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, by and between H.C. Wainwright & Co., LLC and the Company, dated as of September 6, 2019.

AKERS BIOSCIENCES, INC. FORM OF COMMON STOCK PURCHASE WARRANT
Akers Biosciences, Inc. • October 31st, 2018 • In vitro & in vivo diagnostic substances

THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jersey corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • August 13th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of August 11, 2020, between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Securities Purchase Agreement
Securities Purchase Agreement • February 21st, 2023 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (the “Agreement”), dated as of ________________, 2023, is by and among MyMD Pharmaceuticals, Inc., a New Jersey corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

FORM OF PLACEMENT AGENT WARRANT]
Akers Biosciences Inc • April 5th, 2017 • In vitro & in vivo diagnostic substances

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ___________, 20173 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the commencement of sales of the Offering (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jersey corporation (the “Company”), up to ______ shares4 of Common Stock, no par value (“Common Stock”), of the Company, as subject to adjustment hereunder (the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

AKERS BIOSCIENCES, INC. FORM OF COMMON STOCK PURCHASE WARRANT
Akers Biosciences Inc • January 10th, 2017 • In vitro & in vivo diagnostic substances

THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jersey corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

STRICTLY CONFIDENTIAL Akers Biosciences, Inc.
Letter Agreement • August 13th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York
THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL,...
Akers Biosciences, Inc. • December 14th, 2017 • In vitro & in vivo diagnostic substances • New York

THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS ONE YEAR FROM THE EFFECTIVE DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING].

FORM OF SECURITIES PURCHASE AGREEMENT
Form of Securities Purchase Agreement • November 12th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of November 11, 2020, between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

UNDERWRITING AGREEMENT between AKERS BIOSCIENCES, INC. and JOSEPH GUNNAR & CO., LLC as Representative of the Several Underwriters AKERS BIOSCIENCES, INC.
Underwriting Agreement • December 19th, 2017 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

The undersigned, Akers Biosciences, Inc., a corporation formed under the laws of the State of New Jersey (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Akers Biosciences, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Joseph Gunnar & Co., LLC. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:

AKERS BIOSCIENCES, INC. and , as Trustee FORM OF INDENTURE Dated as of ,
Akers Biosciences, Inc. • November 1st, 2019 • In vitro & in vivo diagnostic substances • New York

INDENTURE, dated as of , , by and between Akers Biosciences, Inc., a New Jersey corporation, as Issuer (the “Company”) and , a organized under the laws of , as Trustee (the “Trustee”).

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • November 29th, 2019 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of [__, 2019, between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

FORM OF NONQUALIFIED STOCK OPTION AGREEMENT MYMD PHARMACEUTICALS, INC.
Nonqualified Stock Option Agreement • April 22nd, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New Jersey
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 5th, 2017 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2017, between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

AKERS BIOSCIENCES, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EMPLOYEE
Non-Qualified Stock Option Agreement • December 6th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances

THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) entered into as of the ____ day of ______, 201__ by and between Akers Biosciences, Inc. (the “Company”) and _____________ (the “Optionee”).

FORM OF INCENTIVE STOCK OPTION AGREEMENT
Incentive Stock Option Agreement • April 22nd, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT Akers Biosciences, Inc.
Akers Biosciences, Inc. • November 29th, 2019 • In vitro & in vivo diagnostic substances • New York

THIS SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the date (the “Charter Amendment Date”) on which the Company (as defined below) publicly announces through the filing of a Current Report on Form 8-K that the amendment to the Company’s certificate of incorporation to sufficiently increase the Company’s authorized shares of Common Stock to cover the conversion of all then-outstanding shares of Preferred Stock into Common Stock has been filed with the Secretary of State of the State of New Jersey (the “Termination Date”)1 but not thereafter, to subscribe for and purchase from Akers Biosciences, Inc., a New Jerse

VOTING AGREEMENT
Voting Agreement • November 12th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

This VOTING AGREEMENT (this “Agreement”) is entered into as of November 11, 2020, between MyMD Pharmaceuticals. Inc., a Florida corporation (“Company”) and the undersigned (the “Stockholder”).

WARRANT EXERCISE AGREEMENT
Warrant Exercise Agreement • October 13th, 2017 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances

This Warrant Exercise Agreement (this “Agreement”), dated as of October 12, 2017, is by and between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock, no par value (the “Common Stock”).

AutoNDA by SimpleDocs
INCENTIVE STOCK OPTION AGREEMENT
Incentive Stock Option Agreement • December 6th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances • New York

This Incentive Stock Option Agreement (“Agreement”) is made and entered into as of the date set forth below, by and between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and the employee of the Company named in Section 1(b). (“Optionee”):

AKERS BIOSCIENCES, INC. and VSTOCK TRANSFER, LLC Rights Agent Rights Agreement Dated as of September 9, 2020
Rights Agreement • September 9th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New Jersey

RIGHTS AGREEMENT, dated as of September 9, 2020, between AKERS BIOSCIENCES, INC., a New Jersey corporation (the “Company”), and VSTOCK TRANSFER, LLC (the “Rights Agent”).

AKERS BIOSCIENCES, INC. RESTRICTED STOCK AGREEMENT
Restricted Stock Agreement • December 6th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances

THIS RESTRICTED STOCK AGREEMENT (the “Agreement”) is made and entered into as of the ____ day of __________, 20__ (the “Effective Date”) by and between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), having an address at 201 Grove Road, Thorofare, New Jersey 08086 and __________________ (“Grantee”), having an address at _________________________________________.

Amendment
Amendment • August 19th, 2024 • TNF Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances

This Amendment (this “Amendment”), dated as of August [ ], 2024, is by and among TNF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investor listed on the signature page attached hereto (the “Investor”).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • March 24th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 23, 2020 (the “Execution Date”), is entered into by and between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and the undersigned members (each, individually, a “Seller,” and collectively, “Sellers”) of Cystron Biotech, LLC, a Delaware limited liability company (“Cystron”), identified on the signature pages to that certain Membership Interest Purchase Agreement, by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement.

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • October 31st, 2018 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of October 31, 2018, between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Employment Agreement
Employment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Florida

This Employment Agreement is entered into effective as of November 1, 2020 (the “Effective Date”) by and between MYMD Pharmaceuticals. Inc. (the “Company”) and Chris Chapman, MD (“Employee”).

Securities Purchase Agreement
Securities Purchase Agreement • May 21st, 2024 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (the “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • May 21st, 2024 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2024, is by and among MyMD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).

SUBSCRIPTION AGREEMENT
Subscription Agreement • August 7th, 2013 • Akers Biosciences Inc • New Jersey

THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of June 12, 2013, is by and between Akers Biosciences, Inc., a corporation incorporated under the laws of the State of New Jersey and located at 201 Grove Road, Thorofare, New Jersey 08086 USA (the “Company”), and CHUBEWORKX GUERNSEY LIMITED, a company incorporated in Guernsey with registration number 55801 with its registered office at 18-20 Le Pollet, St Peter Port, Guernsey, GY1 1WH, Channel Islands (“Chubeworkx” or the “Subscriber”). The Company and the Subscriber are sometimes collectively referred to herein as the “Parties” and individually referred to herein as a “Party.”

SHAREHOLDER VOTING AGREEMENT
Shareholder Voting Agreement • March 24th, 2020 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

THIS SHAREHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of March 23, 2020, by and among Akers Biosciences, Inc. (the “Company”) and each of the undersigned Stockholders of the Company (the “Stockholders”).

Akers Biosciences, Inc.
Licence and Supply Agreement • August 7th, 2013 • Akers Biosciences Inc
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
Agreement and Plan of Merger and Reorganization • March 19th, 2021 • Akers Biosciences, Inc. • In vitro & in vivo diagnostic substances • New York

This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made as of March 16, 2020, by and among Akers Biosciences, Inc., a New Jersey corporation (“Parent”), XYZ Merger Sub Inc., a Florida corporation (“Merger Sub”), and MYMD Pharmaceuticals, Inc., a Florida corporation (“Company”). Parent, Merger Sub and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined herein shall have the meanings assigned to them in the Merger Agreement (defined below).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!